Printer Friendly
The Free Library
19,604,530 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Corporate Profile for Cerus Corporation, dated Feb. 21, 2003.


Business Editors

--(BUSINESS WIRE)

The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services.


Published Date:   Feb. 21, 2003

Company Name:     Cerus Corporation

Address:          2411 Stanwell Dr.
                  Concord, CA 94520
                  USA

Main Telephone
 Number:          925/288-6000

Internet Home
 Page Address
  (URL)           www.cerus.com

Chief Executive
 Officer:         Stephen T. Isaacs

Chief Financial
 Officer:         Gregory W. Schafer

Investor Relations
 Contact:         Sylvia R. Wheeler
 Business number: 925/288-6061
 E-mail address:  sylvia_wheeler@cerus.com

Public Relations
 Contact:         Sylvia R. Wheeler

Industry:         Healthcare; Biotech

Trading Symbol/
 Exchange:        CERS



Company Description: Cerus Corporation is building on its leading position in the biopharmaceutical industry by developing medical systems and therapeutics therapeutics

Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry.
 to provide safer and more effective options to patients. The company is developing products based on its proprietary Helinx(R) technology for controlling biological replication In database management, the ability to keep distributed databases synchronized by routinely copying the entire database or subsets of the database to other servers in the network.

There are various replication methods.
. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. The INTERCEPT intercept

in mathematical terms the points at which a curve cuts the two axes of a graph.
 Blood System, based on the company's Helinx technology, is designed to inactivate in·ac·ti·vate
v.
1. To render nonfunctional.

2. To make quiescent.



in·acti·va
 viruses, bacteria, other pathogens and white blood cells White blood cells
A group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system.

Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies
. The Concord Concord, cities, United States
Concord (kŏng`kərd, kŏn`kôrd').

1 city (1990 pop. 111,348), Contra Costa co., W central Calif.; settled c.1852, inc. 1906.
, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Feb 21, 2003
Words:216
Previous Article:Wolfson Launches Second-Generation Stereo Codec for Ultra Low-Power Portable Audio.
Next Article:Corporate Profile for Video Software Dealers Association, dated Feb. 21.
Topics:



Related Articles
CERUS/BAXTER APPLY FOR CE MARK FOR INTERCEPT PLATELET SYSTEM.
Cerus Corporation Names Vice President of Marketing.
Cerus and Baxter Receive FDA Concurrence to Begin Phase III INTERCEPT Red Blood Cell Trial in Chronic Indications.
Cerus Corporation Announces First Quarter Results.
Cerus Corporation to Webcast Fourth Quarter and Year-End Financial Results Conference Call.
Cerus Corporation to Webcast First Quarter Financial Results Conference Call.
Cerus Corporation to Webcast Second Quarter Financial Results Conference Call.
Cerus Corporation to Webcast Second Quarter Financial Results Conference Call.
Cerus Submits IND Application for CRS-100 to FDA.
Cerus Corporation to Webcast Fourth Quarter and Year-End Financial Results Conference Call.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles